Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer

@article{Seidenfeld2000SingleTherapyAS,
  title={Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer},
  author={J. Seidenfeld and D. Samson and V. Hasselblad and N. Aronson and P. Albertsen and C. Bennett and T. Wilt},
  journal={Annals of Internal Medicine},
  year={2000},
  volume={132},
  pages={566-577}
}
  • J. Seidenfeld, D. Samson, +4 authors T. Wilt
  • Published 2000
  • Medicine
  • Annals of Internal Medicine
  • Androgen ablation delays clinical progression and palliates symptoms of metastatic disease in men with advanced prostate cancer (1-4). The earliest method was orchiectomy, and diethylstilbestrol (DES) subsequently became the first reversible method (5-7). Newer alternatives include luteinizing hormone-releasing hormone (LHRH) agonists, such as leuprolide, goserelin, and buserelin (8-10), and nonsteroidal antiandrogens, such as flutamide, nilutamide, and bicalutamide (11-13). Cyproterone acetate… CONTINUE READING
    400 Citations
    Androgen Deprivation Therapy for Advanced Prostate Cancer
    Endocrine treatment of prostate cancer
    • T. Tammela
    • Medicine
    • The Journal of Steroid Biochemistry and Molecular Biology
    • 2004
    • 87

    References

    SHOWING 1-10 OF 72 REFERENCES
    Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
    • A. Chang, B. Yeap, +8 authors D. Trump
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1996
    • 113
    • Highly Influential
    Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    • 70
    • Highly Influential
    A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.
    • 88